Navigation Links
Adynxx Enrolls First Patient in Phase 2 Proof-of-Concept Study for AYX1, Lead Compound for the Prevention of Post-Surgical Pain
Date:2/25/2013

SAN FRANCISCO, Feb. 25, 2013 /PRNewswire/ -- Adynxx, a clinical-stage pharmaceutical company developing a first-in-class platform of therapeutics to address pain at its molecular roots, announced today that the first patient was dosed in a Phase 2 study of its lead investigational drug candidate for the prevention of post-surgical pain, AYX1.

The 90-patient, placebo-controlled study will evaluate the safety and efficacy of a single administration of AYX1 given prior to unilateral total knee arthroplasty (TKA) to reduce acute pain and to prevent the transition to persistent pain. The study will follow patients for 42 days, with a primary endpoint of pain with walking. Secondary and exploratory endpoints will include pain at rest, pain with knee range of motion, rate and extent of functional recovery, opioid consumption and safety assessments. Further details of the study can be found at www.clinicaltrials.gov

"While many widely used pain therapies require repeat dosing for symptom amelioration, or require heavy dosing with associated side-effects to treat pain with movement, a single administration of AYX1 has the potential to block the development of pain before it begins," said Donald Manning , M.D., Ph.D., chief medical officer of Adynxx. "This study will evaluate AYX1's ability to reduce acute pain and prevent persistent pain, especially pain associated with movement, enabling patients to begin rehabilitation and resume other activities earlier."

Dennis Podlesak , chairman of the Adynxx board of directors, added, "AYX1 is a novel new treatment option that has the potential to transform how patients suffering from post-surgical pain are treated, and to provide patients and physicians with an innovative and advantageous approach to pain management.  The clinical and preclinical results to date
'/>"/>

SOURCE Adynxx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Lead Therapeutic Candidate for Treatment of Pain from Adynxx, AYX1, Well-Tolerated in Phase 1 Clinical Study
2. Adynxx Completes Enrollment in Phase 1 Clinical Study of Lead Therapeutic for Treatment of Pain, AYX1
3. Boehringer Ingelheim Enrolls First Patients in Pivotal Phase 3 Interferon-Free Hepatitis C Trial Program
4. CalHIPSO Enrolls Over 7,700 Providers in EHR Implementation Program, Hits Other Key Milestones After First Two Years
5. First U.S. Patients Treated in PneumRx RENEW Pivotal Study for Treatment of Severe Emphysema
6. The Emirate of Abu Dhabi Becomes First to Have JCI Accredited Long-Term Care Facility Outside of USA
7. Specialty Pharmacy Association of America (SPAARx) - Enrollment Exceeds 1,000 Members in First Two Weeks since Launch
8. Research Units Across the World go for the First 3 Tesla, Cryogen Free MRI Bench Top Scanner
9. Perrigo Confirms First to File Patent Challenge for Generic Version of Testosterone Gel 1.62%
10. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
11. Smt. Sheila Dikshit Unveils South Asias First PET SUITE at Indraprastha Apollo Hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... BALTIMORE and CAMBRIDGE, Mass. ... Diagnostics Inc. (PGDx), a provider of advanced ... Blueprint Medicines , a leader in discovering and ... cancers, today disclosed the first-ever comprehensive genomic study ... and deadly cancer of the female reproductive system, ...
(Date:9/19/2014)... , Sept. 19, 2014  PCI is ... International (Biotec).  Biotec is a leading provider of ... headquartered in Bridgend, Wales ...  The addition significantly expands PCI,s presence in the ... products by adding packaging, storage and distribution capacity, ...
(Date:9/18/2014)... Sept. 18, 2014  Low T Center endorses ... in Hyattsville, Maryland earlier ... the proper patient population for testosterone therapy (TRT), ... associated with TRT. Examining recent claims from studies that ... "available epidemiological studies do not provide convincing evidence ...
Breaking Medicine Technology:First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4PCI Announces Acquisition Of Biotec 2PCI Announces Acquisition Of Biotec 3PCI Announces Acquisition Of Biotec 4PCI Announces Acquisition Of Biotec 5PCI Announces Acquisition Of Biotec 6Low T Center Endorses The Joint FDA Committee Meeting on Testosterone 2
... June 8, 2011 Medco Health Solutions, Inc. (NYSE: ... its groundbreaking SOCRxATES® community pharmacy program to ... SOCRxATES is a care improvement program that enables ... medical conditions and gaps in care, such as medication ...
... 2011 CANTEL MEDICAL CORP. (NYSE: CMN ... $0.29 per diluted share, on a 24% increase in sales to ... This compares with net income of $4,274,000, or $0.25 per diluted ... 30, 2010.  For the nine months ended April 30, 2011, the ...
Cached Medicine Technology:Medco, State of New Mexico and Community Pharmacists Launch SOCRxATES® Program to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 2Medco, State of New Mexico and Community Pharmacists Launch SOCRxATES® Program to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 3Medco, State of New Mexico and Community Pharmacists Launch SOCRxATES® Program to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 4Cantel Medical Reports 18% Increase in Net Income on 24% Increase in Sales 2Cantel Medical Reports 18% Increase in Net Income on 24% Increase in Sales 3Cantel Medical Reports 18% Increase in Net Income on 24% Increase in Sales 4Cantel Medical Reports 18% Increase in Net Income on 24% Increase in Sales 5
(Date:9/21/2014)... The prevalence of preterm birth the birth of ... is a significant health problem that has increased over ... for Disease Control and Prevention (CDC), preterm birth affects ... eight born in the U.S. While medical care has ... ways to positively impact the neurodevelopmental outcomes of preterm ...
(Date:9/21/2014)... AstraZeneca’s Pulmicort is an ICS ... is used prophylactically for the maintenance treatment of ... budesonide, is an anti-inflammatory corticosteroid with a high ... includes the Pulmicort Flexhaler (budesonide) for adults and ... Pulmicort Respules for children between one and eight ...
(Date:9/21/2014)... 22, 2014 PhUSE is proud to ... Lilliam Rosario as keynote speakers for their 10th annual ... Dr. Ben Goldacre in 2013 , Charles ... in 2011 , PhUSE again presents high-calibre speakers to ... about advancement of clinical information. , Dr. Pritpal Tamber ...
(Date:9/21/2014)... September 21, 2014 The Laboratory Testing ... and manufacturers perform tests on items ranging from consumer ... regulated society, pressure on operators to ensure the safety ... A greater number of government safety regulations and consumer ... prior to sale. Although revenue briefly dipped in 2009 ...
(Date:9/21/2014)... Texas (PRWEB) September 22, 2014 ... the past decade, as it has become saturated ... beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and ... also been facing increasing generic competition. However, the ... once-daily ICS and ICS/LABA therapies delivered by the ...
Breaking Medicine News(10 mins):Health News:Research evaluates neurodevelomental and medical outcomes in single family room NICU 2Health News:Research evaluates neurodevelomental and medical outcomes in single family room NICU 3Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:PhUSE announces Final List of Industry Influencers as Keynote Speakers 2Health News:PhUSE announces Final List of Industry Influencers as Keynote Speakers 3Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4
... shown to prevent the transmission of HIV as well. Experiments ... or reduce the painful open sores of chancroid on the ... ,Chancroid is a highly contagious STD that is ... United States as well. Antibiotics can be used to effectively ...
... are considered to be a high tech machine and are ... working hard to make it otherwise//. There is a big ... and confusion. Dr J?rg Voskamp, from Germany's Fraunhofer Institute plans ... one’s emotions. A sensitive PC is a research project and ...
... a baby was stillborn last week. But the baby was alive ... before finally succumbing on Saturday. ,Born to Rakesh and ... Rakesh, an auto driver, took him to the burial ground, the ... intensive care unit of the hospital. ,The baby was delivered ...
... A married couple who tried to hoodwink authorities by tying ... collect Rs 5000/- as a reward have been hauled away ... were married 15 years ago and have three children. ... government's mass marriage promotion scheme under which Rs.5,000 is given ...
... 14 which is marked for the celebration of Mother’s day ... India. According to the statistics released by UNICEF// in India ... the world scenario this accounts to more than 20% of ... births there are about 540 maternal deaths. ,There ...
... were investigating eight suspected bird flu cases in humans in ... had been fatal. ,A team from the WHO ... can say they are still suspect at the moment," said ... the Health Ministry's office of communicable disease control, added that ...
Cached Medicine News:Health News:UNICEF Facts & Figures About Maternal Death In India On The Eve Of Mother’s Da 2Health News:UNICEF Facts & Figures About Maternal Death In India On The Eve Of Mother’s Da 3
... Auto Suture™ PREMIUM SURGICLIP™ clip applier consists of ... cartridge containing 15 or 20 titanium clips. , ... a vessel or other tubular structure. As the ... clip is closed around the vessel or structure. ...
... single use stapler places two titanium staples ... and a knife which divides the tissue ... ,The Auto Suture™ Powered LDS™ single use ... abdominal, gynecological, orthopedic, and thoracic surgery for ...
The ALLPORT and ALLPORT LS Endoscopic Rotating Multiple Clip Appliers have application for use on tubular structures or vessels. The tissue being ligated should be consistent with the size of the cli...
... 20/20 Multiple Clip Applier is a sterile ... This automatic instrument is preloaded with 20 ... by means of the unique Klieman feed ... is reloadable once with a reload containing ...
Medicine Products: